Genliang Lu

1.3k total citations
20 papers, 862 citations indexed

About

Genliang Lu is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Organic Chemistry. According to data from OpenAlex, Genliang Lu has authored 20 papers receiving a total of 862 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Radiology, Nuclear Medicine and Imaging and 7 papers in Organic Chemistry. Recurrent topics in Genliang Lu's work include Radiopharmaceutical Chemistry and Applications (8 papers), Advanced biosensing and bioanalysis techniques (4 papers) and Prostate Cancer Treatment and Research (4 papers). Genliang Lu is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (8 papers), Advanced biosensing and bioanalysis techniques (4 papers) and Prostate Cancer Treatment and Research (4 papers). Genliang Lu collaborates with scholars based in United States, United Kingdom and Canada. Genliang Lu's co-authors include William C. Eckelman, Kevin Maresca, John W. Babich, John L. Joyal, Shawn Hillier, Craig Zimmerman, Helena C. Malinakova, John C. Marquis, Kevin Burgess and Ross D. Merkin and has published in prestigious journals such as Nature Biotechnology, Cancer Research and Chemical Communications.

In The Last Decade

Genliang Lu

20 papers receiving 843 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Genliang Lu United States 14 370 343 273 239 160 20 862
Vadim Divilov United States 9 276 0.7× 597 1.7× 275 1.0× 236 1.0× 397 2.5× 16 1.1k
Victor Gonçalves France 20 488 1.3× 395 1.2× 131 0.5× 243 1.0× 243 1.5× 42 1.0k
Alan Cuthbertson Norway 22 380 1.0× 925 2.7× 368 1.3× 184 0.8× 377 2.4× 52 1.4k
Annemarie Eek Netherlands 19 279 0.8× 692 2.0× 241 0.9× 116 0.5× 501 3.1× 28 1.2k
Nadine Colpo Canada 18 166 0.4× 534 1.6× 217 0.8× 95 0.4× 307 1.9× 41 766
Sarah M. Cheal United States 19 320 0.9× 490 1.4× 206 0.8× 85 0.4× 285 1.8× 36 1.0k
Keith Graham Germany 19 373 1.0× 699 2.0× 199 0.7× 213 0.9× 392 2.5× 36 1.2k
Jin‐Cong Zhuo Switzerland 14 244 0.7× 165 0.5× 95 0.3× 245 1.0× 208 1.3× 38 762
Curtis Harwig Canada 17 286 0.8× 243 0.7× 63 0.2× 332 1.4× 199 1.2× 27 833
Mark D. Hylarides United States 20 297 0.8× 716 2.1× 142 0.5× 171 0.7× 259 1.6× 49 1.1k

Countries citing papers authored by Genliang Lu

Since Specialization
Citations

This map shows the geographic impact of Genliang Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Genliang Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Genliang Lu more than expected).

Fields of papers citing papers by Genliang Lu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Genliang Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Genliang Lu. The network helps show where Genliang Lu may publish in the future.

Co-authorship network of co-authors of Genliang Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Genliang Lu. A scholar is included among the top collaborators of Genliang Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Genliang Lu. Genliang Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Deprey, Kirsten, Marjoke F. Debets, Kirstin B. VanderWall, et al.. (2022). Quantitative Measurement of Cytosolic and Nuclear Penetration of Oligonucleotide Therapeutics. ACS Chemical Biology. 17(2). 348–360. 18 indexed citations
2.
Iwamoto, Naoki, David C. Butler, Nenad Svrzikapa, et al.. (2017). Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides. Nature Biotechnology. 35(9). 845–851. 263 indexed citations
3.
Panzara, Michael, Carlo Rinaldi, Graham McClorey, et al.. (2017). Preclinical studies of WVE-210201, an investigational stereopure antisense oligonucleotide in development for the treatment of patients with duchenne muscular dystrophy (DMD). Journal of the Neurological Sciences. 381. 277–278. 1 indexed citations
4.
Wood, Matthew J. A., Keith Bowman, David Butler, et al.. (2017). WVE-210201, an investigational stereopure oligonucleotide therapy for Duchenne muscular dystrophy, induces Exon 51 skipping and dystrophin protein restoration. Neuromuscular Disorders. 27. S217–S217. 4 indexed citations
5.
Ying, Weiwen, Dinesh Chimmanamada, Junyi Zhang, et al.. (2014). Abstract 1619: Hsp90 inhibitor drug conjugates (HDCs): Construct design and preliminary evaluation. Cancer Research. 74(19_Supplement). 1619–1619. 2 indexed citations
6.
Hillier, Shawn, Kevin Maresca, Genliang Lu, et al.. (2013). 99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer. Journal of Nuclear Medicine. 54(8). 1369–1376. 183 indexed citations
7.
Hillier, Shawn, Kevin Maresca, Genliang Lu, et al.. (2013). 99m Tc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer. 14 indexed citations
8.
Lu, Genliang, Kevin Maresca, Shawn Hillier, et al.. (2012). Synthesis and SAR of 99mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates. Bioorganic & Medicinal Chemistry Letters. 23(5). 1557–1563. 72 indexed citations
9.
Maresca, Kevin, Shawn Hillier, F.J. Femia, et al.. (2012). Development of a simple kit for Tc-99m-MIP-1404, a single amino acid chelate (SAAC II) derived small molecule inhibitor of prostate specific membrane antigen (PSMA) for imaging prostate cancer. 53. 523–523. 8 indexed citations
10.
Hillier, Shawn, Genliang Lu, Kevin Maresca, et al.. (2012). Evaluation of 99mTc-labeled small molecule inhibitors of carbonic anhydrase (CA) for imaging hypoxia. 53. 217–217. 1 indexed citations
11.
Maresca, Kevin, Shawn Hillier, Genliang Lu, et al.. (2012). Small molecule inhibitors of PSMA incorporating technetium-99m for imaging prostate cancer: Effects of chelate design on pharmacokinetics. Inorganica Chimica Acta. 389. 168–175. 25 indexed citations
12.
Kothari, Paresh J., Shankar Vallabhajosula, Genliang Lu, et al.. (2012). 18F-labeled small molecule inhibitors of prostate specific membrane antigen (PSMA) for PET imaging of prostate cancer. 53. 1721–1721. 1 indexed citations
13.
Lu, Genliang, Shawn Hillier, Kevin Maresca, et al.. (2012). Synthesis and SAR of Novel Re/99mTc-Labeled Benzenesulfonamide Carbonic Anhydrase IX Inhibitors for Molecular Imaging of Tumor Hypoxia. Journal of Medicinal Chemistry. 56(2). 510–520. 36 indexed citations
14.
Maresca, Kevin, John C. Marquis, Shawn Hillier, et al.. (2010). Novel Polar Single Amino Acid Chelates for Technetium-99m Tricarbonyl-Based Radiopharmaceuticals with Enhanced Renal Clearance: Application to Octreotide. Bioconjugate Chemistry. 21(6). 1032–1042. 54 indexed citations
15.
Lu, Genliang & Kevin Burgess. (2006). A diversity oriented synthesis of 3′-O-modified nucleoside triphosphates for DNA ‘sequencing by synthesis’. Bioorganic & Medicinal Chemistry Letters. 16(15). 3902–3905. 17 indexed citations
16.
Lu, Genliang, et al.. (2006). An iterative route to “decorated” ethylene glycol-based linkers. Chemical Communications. 1652–1652. 53 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026